Managing Diarrhea on Zepbound (tirzepatide): The HealthRX.com Step-by-Step Protocol

How common is diarrhea on Zepbound?

The label pools two placebo-controlled weight-management trials (SURMOUNT-1 and SURMOUNT-2) covering 2,519 adults treated for up to 72 weeks [1]. Diarrhea — a term the label says also includes frequent bowel movements — was reported by 8% of the placebo group, 19% of the 5 mg group, 21% of the 10 mg group and 23% of the 15 mg group [1]. Rates rise with dose.

Gastrointestinal reactions as a whole were far more common than diarrhea alone: 56% at every Zepbound dose versus 30% on placebo [1].

Severe gastrointestinal reactions were reported by 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, versus 1% on placebo [1]. Treatment was permanently stopped because of a GI reaction by 1.9%, 3.3% and 4.3% of patients at those doses, versus 0.5% on placebo [1].

When does it usually start?

The label states that the majority of nausea, vomiting and/or diarrhea events occurred during dose escalation and decreased over time [1]. Tirzepatide is a dual GIP and GLP-1 receptor agonist that delays gastric emptying, and the label says that delay is largest after the first dose and diminishes over time [1].

The Zepbound label says gradual dose increases are intended to reduce gastrointestinal adverse reactions [1]. The dose is increased in 2.5 mg increments after at least 4 weeks on the current dose [1]. Most patients who stopped Zepbound because of an adverse reaction did so in the first few months of treatment, for gastrointestinal reasons [1].

What the label says about dose steps and a lower maintenance dose

Zepbound starts at 2.5 mg once weekly for 4 weeks — an initiation dose that the label says is not approved as a maintenance dose — then 5 mg, with 2.5 mg increases after at least 4 weeks at the current dose [1]. Maintenance for weight reduction is 5, 10 or 15 mg once weekly; for obstructive sleep apnea it is 10 or 15 mg; the maximum is 15 mg weekly [1].

The label says to consider treatment response and tolerability when selecting the maintenance dose, and that if patients do not tolerate a maintenance dose, a lower maintenance dose should be considered [1]. That is the label's own stepwise answer to GI intolerance, and it is not specific to diarrhea as opposed to nausea or vomiting. Zepbound is also not recommended in people with severe gastroparesis [1].

What to watch for: fluid loss and kidney injury

The label describes postmarketing reports of acute kidney injury, some requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Zepbound [1]. Most of those events occurred in patients who had gastrointestinal reactions leading to dehydration, such as nausea, vomiting or diarrhea [1]. It instructs clinicians to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1]. No dose adjustment is recommended for renal or hepatic impairment [1].

When diarrhea needs medical attention

The label says to observe patients carefully after starting Zepbound for signs of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by nausea or vomiting [1]. If pancreatitis is suspected, the label says to discontinue Zepbound and begin appropriate management [1].

The label also lists acute gallbladder disease: cholecystitis was reported in 0.7% of Zepbound-treated patients versus 0.2% on placebo, and the label says gallbladder studies and clinical follow-up are indicated if cholecystitis is suspected [1].

Does the label name a treatment for diarrhea?

No. The Zepbound label names no antidiarrheal medicine, probiotic or rehydration product. In SURMOUNT-5, a 751-adult head-to-head trial of tirzepatide versus semaglutide over 72 weeks, the most common adverse events in both groups were gastrointestinal and most were mild to moderate [2]. For GI tolerability, the label calls for at least 4 weeks between 2.5 mg dose increases and says to consider a lower maintenance dose if the current one is not tolerated [1].